Robert W. Baird Reaffirms Neutral Rating for Biogen Inc.


's stock had its "neutral" rating reiterated by equities researchers at Robert W. Baird in a report issued on Saturday. They presently have a $284.00 target price on the biotechnology company's stock.



from Biotech News